Biotech and Pharmaceuticals Pharmaceuticals

  • FDA: Eli Lilly drug reduces cardiovascular death

    Shares of Eli Lilly gains momentum on news of an FDA drug approval. CNBC's Seema Mody reports.

  • There are a lot of incompetent boards but this one takes the cake: Swisher

    Kara Swisher, Recode executive editor, shares her take on the Theranos board, calling it "the most unusual board in Silicon Valley."

  • Dec 2- Amgen Inc and Allergan Plc said they have submitted an application to the European health regulator seeking approval of their biosimilar version of Roche Holding AG's blockbuster cancer treatment, Avastin. The submission is based on the results of a late-stage study that showed Amgen and Allergan's ABP 215 was as safety and effective as Avastin in...

  • NEW YORK, Dec 1- Top executives from large U.S. drugmakers on Thursday discussed for the first time possible changes for the industry under President-elect Donald Trump, and issues that have damaged the reputation of their industry. Since he was elected, Trump, who has said he wants to repeal Obamacare and reform Medicare and Medicaid, has not addressed the sharp...

  • Allergan CEO: We're in era of populism & drug industry is unpopular

    CNBC's Meg Tirrell speaks to Brent Saunders, Allergan CEO, about the drug industry's new era under a Trump presidency.

  • Since he was elected, Trump, who has said he wants to repeal Obamacare and reform Medicare and Medicaid, has not addressed the sharp drug price increases that dominated the Presidential campaign. Pharma companies are breathing a sigh of relief, but Trump could be more critical of drugmakers and their price increases than the industry expects, Allergan Inc Chief...

  • President-elect Donald Trump could be more critical of drugmakers and their price increases than the industry expects, Allergan Inc Chief Executive Brent Saunders said on Thursday. Saunders on Thursday said drugmakers should not expect Trump or Congress to be any less critical of price increases after Trump takes office in January. "I worry today that the...

  • Regeneron CEO on drug pricing

    CNBC's Meg Tirrell speaks to Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, about Trump's effect on biotech, drug pricing and the study against high cholesterol.

  • Nelson: Optimistic about innovation possibly impacting cancer

    CNBC's Meg Tirrell speaks to Robert Nelsen, ARCH Venture Partners founder, about Trump's potential impact on the drug industry, and the future of biotech.

  • Kenneth Frazier, CEO of Merck.

    Kenneth Frazier, the CEO of pharmaceutical giant Merck, says Trump's call to revamp Obamacare could prove useful.

  • Bringing drugs in from outside the US is actually a dangerous concept: Merck CEO

    CNBC’s Meg Tirrell talks to Kenneth Frazier, Merck CEO, at the fifth annual Forbes Healthcare Summit in New York about the future of drug pricing under the Trump administration as well as Alzheimer’s research.

  • Steven Cohen, Chairman and CEO of Point72 Asset Management.

    Billionaire Steven A. Cohen's former hedge fund SAC Capital Advisors has agreed to pay $135 million to resolve a lawsuit.

  • NEW YORK, Nov 30- Billionaire Steven A. Cohen's former hedge fund SAC Capital Advisors LP will pay $135 million to settle a lawsuit by investors in the drugmaker Elan Corp, who said they lost money because of insider trading by one of his portfolio managers. The preliminary class-action settlement with SAC, now known as Point72 Asset Management LP, was filed on...

  • NEW YORK, Nov 30- Billionaire Steven A. Cohen's former hedge fund SAC Capital Advisors LP will pay $135 million to settle a lawsuit by investors in Elan Corp, who said they lost money on the drugmaker due to insider trading by one of his portfolio managers. It resolves class-action claims over an estimated $275 million of illegal gains that Mathew Martoma, who...

  • Sources: Valeant-Takeda deal is 'all but dead'

    Sources say the Valeant-Takeda deal is "all but dead." CNBC's Scott Wapner reports the details, as well as how the market is reacting to this news.

  • Nov 30- Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin was found comparable with the branded version in a key study. Unlike generic drugs, which are interchangeable with their branded counterparts, biosimilars approved by the U.S. Food and Drug Administration to date are not...

  • Nov 30- Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin met the main goal in a key study. Pfizer tested the safety and effectiveness of the drug, PF-05280014, in combination with chemotherapeutic agent paclitaxel against Herceptin and paclitaxel in previously untreated...

  • But their objections were overwhelmed by an alliance among Republicans, many Democrats and the White House for a 996- page measure that bore wins for both parties. The Senate's expected final approval next week would mark an uncommon episode of cooperation between the GOP- run 114th Congress— which plans to adjourn next week— and President Barack Obama in their...

  • Mark Trudeau, chief executive officer of Mallinckrodt Plc

    Mallinckrodt said it experienced "production issues" with a third-party manufacturer supporting its immunotherapy platform, Therakos.

  • BATTLE CREEK, Mich.— Kellogg has announced that it will no longer advertise on Breitbart.com, the website formerly run by one of President-elect Donald Trump's top aides, Steve Bannon. The food manufacturer decided to discontinue advertising on the site as soon as it was alerted by consumers to the presence of its ads, Kellogg Co. spokeswoman Kris Charles said...